1
R 100 mg/kg Triphala 5 times a week. Our results are consistent with previous studies where Triphala was shown to be effective in suppressing the growth ofPage 10 of(page number not for citation purposes)BMC Cancer 2008, 8:http://www.biomedcentral.com/1471-2407/8/.' .' .' .'0 0.5 1 2 4of cells with DCF fluorescenceS (5. 7KU 7U SS 6HU16 12 8 43 53 FOHDYHGFWLQTPL treatment (hours)1 P0 73/ J PO0.'
1
Esults. Embryos at high stage (3 1/3 hpf), 50 epiboly (5 1/4 hpf), 70 epiboly (7 hpf) and tailbud stage (10 hpf) were deyolked, separated by SDS-gel electrophoresis and Coomassie stained (A) or blotted and immunodetected with antibodies against Tubulin (55 kD) and Moesin (78/80 kD apparent molecular weight) (B). Note that total protein amount was lower in deyolked samples, therefore more embryos
1
R 100 mg/kg Triphala 5 times a week. Our results are consistent with previous studies where Triphala was shown to be effective in suppressing the growth ofPage 10 of(page number not for citation purposes)BMC Cancer 2008, 8:http://www.biomedcentral.com/1471-2407/8/.' .' .' .'0 0.5 1 2 4of cells with DCF fluorescenceS (5. 7KU 7U SS 6HU16 12 8 43 53 FOHDYHGFWLQTPL treatment (hours)1 P0 73/ J PO0.'
1
Assays of GBM cells stably transfected to over-express galectin-1, perfectly fit in with the previous studies mentioned above and highlight the importance of galectin-1 in the biologically aggressive behavior of experimental GBMs. While there was no enhancement of proliferation or change inattachment to fibronectin, galectin-1 upregulation induced more rapid two-dimensional migration and enhanced
1
Ss microarray chip platforms when hybridizing the same sample RNA [32]. Additionally,Toussaint et al. Molecular Cancer 2012, 11:32 http://www.molecular-cancer.com/content/11/1/Page 8 ofFigure 4 (A) Galectin-1 transfection does not alter U87MG attachment to fibronectin. Attachment to fibronectin-coated 96-well plates was quantitated with an MTT assay with and without a media change in the middle of
1
Nostics, INC, New Jersey) along with a human-specific mouse monoclonal anti-vimentin antibody (Dakocytomation,Toussaint et al. Molecular Cancer 2012, 11:32 http://www.molecular-cancer.com/content/11/1/Page 4 ofTrappes, France). After incubation with the provided goat anti-mouse secondary antibody, staining developed with NovaRed Developing Reagent (Vector Laboratories, Burlingame, CA). Sections we
1
Esthesia. At the onset of neurological symptoms, animals were sacrificed in accordance with the Mayo Clinic IACUC. Survival curves were generated from those animals (38 of 40) developing tumors (7 of 20 acGFP-only).xenograft lines is necessary to characterize completely the in vivo phenotypic alterations that accompany overexpression of galectin-1.Our model system has identified galectin-1 as a ma
1
Y used model system for the analysis of vertebrate embryogenesis and organ development. While genetic methods are readily available in zebrafish, protocols for two dimensional (2D) gel electrophoresis and proteomics have yet to be developed. Results: As a prerequisite to carry out proteomic experiments with early zebrafish embryos, we developed a method to efficiently remove the yolk from large ba

What is Kliqqi?

Kliqqi is an open source content management system that lets you easily create your own user-powered website.

Latest Comments